Last Updated: March 1, 2026Reviewed by: Andrei Dokukin, MDRegulatory Status: Clinical Evidence (Tier 2)GRADE: Low

Mixed Evidence Tiers

Dermatological applications span two evidence tiers. Wound healing has Tier 2 evidence (published clinical studies). All other applications — psoriasis, eczema, scleroderma, erysipelas, joint disease, eponymous syndromes — are Tier 3 (investigational). No dermatologic indication is included in the FDA 510(k) clearance for medicinal leeches.

Investigational Application

Dermatology is not included in the FDA 510(k) clearance for medicinal leeches. The information below summarizes international clinical experience and published research. ASH advocates for rigorous clinical evaluation of these applications.

International Clinical Evidence

The following evidence reflects international clinical experience. Practice standards, regulatory frameworks, and levels of evidence vary by jurisdiction. U.S. practitioners should refer to FDA guidance and applicable state regulations.

Dermatologic and connective tissue applications occupy a distinctive position in hirudotherapy literature. The evidence consists of small patient cohorts and heterogeneous disease categories, yet the pathophysiologic rationale is among the strongest in the field: skin diseases involve inflammation, microvascular dysfunction, immune dysregulation, and fibrosis — all processes targeted by specific, well-characterized salivary gland secretion (SGS) components.

Биологическое обоснование

Anti-Inflammatory Protease Inhibition

Eglins inhibit neutrophil elastase and cathepsin G. Bdellins inhibit trypsin and plasmin. LDTI attenuates mast cell tryptase — particularly relevant to eczema and urticaria where mast cell degranulation drives pathogenesis.

Mast Cell Antagonism

SGS contains coordinated antagonists: antihistamine compounds, antiserotonin factors, a PAF inhibitor, and tryptase-blocking LDTI. Directly relevant to eczema, psoriasis, urticaria, and keloid formation.

Microcirculation Enhancement

Histamine-like vasodilator and hyaluronidase enhance local blood flow. In scleroderma (microvascular obliteration) and varicose eczema (venous stasis hypoxia), restored perfusion addresses root pathophysiology.

Immune Modulation

SGS stimulates T-cells while suppressing B-cells. Eglin c potentiates glucocorticoid activity. Relevant to SLE and scleroderma, though no clinical study has measured immune parameters in HT-treated dermatology patients.

Tissue Remodeling

Collagenase and destabilase-mediated fibrinolysis may soften fibrotic tissue in scleroderma, keloids, and Dupuytren contracture. Hyaluronidase facilitates SGS penetration into indurated tissue.

Antimicrobial Activity

Destabilase-lysozyme exhibits direct antimicrobial properties. In erysipelas and chronic pyoderma, this may complement anti-inflammatory effects and contribute to sustained clearance and reduced recurrence.

Convergent Pharmacology

Skin conditions may respond through multiple SGS mechanisms simultaneously — anti-inflammatory protease inhibitors, mast cell antagonism, microcirculatory enhancement, and tissue remodeling enzymes represent overlapping therapeutic pathways potentially accounting for the consistent positive outcomes reported across independent investigators.

Заживление ран (уровень 2 — клинические доказательства)

Clinical Evidence — Not FDA-Evaluated

Published clinical studies demonstrate SGS promotion of tissue repair through fibroblast proliferation, neovascularization, and antimicrobial protection. Not FDA-cleared for this indication.

GRADE Evidence Level: Low

Observational studies or RCTs with serious limitations

Diabetic Foot Ulcers

Eldor et al. (2016): 67% complete healing at 16 weeks with adjunct hirudotherapy vs 41% standard care (p<0.05, n=52). SGS microcirculatory enhancement is particularly relevant in diabetic microangiopathy.

Chronic Venous Ulcers

Venous stasis pathophysiology — congestion, tissue hypoxia, inflammatory mediator accumulation — is directly addressed by SGS anticoagulant, decongestive, and anti-inflammatory properties. Published series report pronounced improvement with perilesional application.

Wound healing studies with clinical outcome data
Study	Design	Population (n=)	Intervention	Key Outcome	Result
Eldor et al. 2016	Prospective cohort	Diabetic foot ulcers (n=52)	Adjunct hirudotherapy to standard wound care	Ulcer healing rate at 16 weeks	67% complete healing vs 41% standard care (p<0.05) Specialized wound care setting; careful patient selection
Michalsen et al. 2008	Pilot RCT	Post-herpetic neuralgia with skin changes (n=40)	Hirudotherapy (2 sessions) vs topical lidocaine	Pain and skin healing	Greater pain reduction and improved skin appearance in leech group Small exploratory study; replication needed

Воспалительные заболевания кожи (уровень 3 — исследовательские)

Investigational / Research Priority

Inflammatory skin disease applications are investigational. No RCT has been performed for any inflammatory dermatologic indication.

GRADE Evidence Level: Very Low

Case reports, case series, or expert opinion only

Psoriasis

Mgaloblishvili et al. (1941) and Pirkhalava et al. (1941) described leech application to psoriatic plaques using the Abuladze method. By days 4-5, plaque fading was observed: infiltrate resolved and general condition improved. Relapses showed less intense manifestations. The sustained 1-3 month post-treatment benefit suggests a disease-modifying rather than symptomatic effect.

Koebner Phenomenon

Psoriasis is susceptible to the Koebner phenomenon — new lesions at trauma sites. The triradiate leech bite could theoretically provoke new plaques at the application site. This risk has not been systematically evaluated and warrants prospective assessment before broad clinical recommendation.

Chronic Eczema & Varicose Eczema

Rybakova (1998) reported pronounced improvement in varicose eczema — reduced erythema, infiltration, and pruritus. The rationale is strong: venous stasis, tissue hypoxia, and inflammatory mediator accumulation are directly addressed by SGS properties. The mast cell antagonism profile (antihistamine, anti-PAF, LDTI) is mechanistically relevant but has not been cross-referenced in dermatology literature.

Erysipelas

Bondarevsky (1998) treated 23 patients with lower leg erysipelas. Pain regressed, infiltration resolved, and zero recurrences were observed at 24 months.

Erysipelas Recurrence

Zero recurrence at 24 months is noteworthy: erysipelas recurs in 30-40% of patients within 3 years despite antibiotics. While n=23 precludes definitive conclusions, the result suggests sustained anti-inflammatory and antimicrobial effect via destabilase-lysozyme.

Other Inflammatory Conditions

Condylomata acuminata: Bondarevsky (1995, 1999) reported accelerated HPV wart regression except at external urethral meatus — likely via improved immune surveillance rather than direct antiviral effect. Chronic pyoderma: Rybakova (1998) used a dual-site approach — meridian acupoints plus direct lesional application (4-6 leeches, 10-20 min).

Published reports — inflammatory skin disease
Study	Design	Population (n=)	Intervention	Key Outcome	Result
Mgaloblishvili et al. 1941	Case series	Psoriasis vulgaris (n=NR)	Leech application to plaques (Abuladze method)	Plaque morphology, relapse frequency	Plaque fading by days 4-5; remission sustained 1-3 months Pre-PASI era; corroborated by Pirkhalava (1941)
Bondarevsky 1998	Case series	Erysipelas of the lower leg (n=23)	Local hirudotherapy to affected area	Pain, infiltration, recurrence at 2 years	Pain resolved; zero recurrences at 24 months Historical recurrence rate 30-40% at 3 yrs with antibiotics
Rybakova 1998	Case series	Morphea, varicose eczema, chronic pyoderma (n=NR)	4-6 leeches; meridian + lesion sites; 10-20 min	Erythema, induration, pruritus, follicular function	Reduced erythema/pruritus; softened induration; hair regrowth in morphea Hair regrowth = restored dermal microcirculation marker

Склеродермия и заболевания соединительной ткани (уровень 3)

Investigational / Research Priority

Scleroderma and connective tissue applications are investigational. Evidence is limited to case series and expert recommendations.

Rybakova (1998) treated morphea using meridian-based application targeting both acupuncture meridians and lesion sites. Results: reduced erythema, softened induration, decreased pruritus, and hair regrowth within plaques — a marker of restored follicular function and dermal microcirculation. Extremity pain resolved.

Three SGS mechanisms converge: collagenase (enzymatic degradation of excess collagen), hyaluronidase (tissue permeability in indurated skin), and protease inhibitors(reduced fibrogenic stimulation). Mgaloblishvili (1941) and Bottenberg (1983) recommended hirudotherapy for SLE, predating modern immunology. SGS T-cell stimulation and B-cell suppression are theoretically relevant but unvalidated clinically.

Артрология: заболевания суставов (уровень 3)

Investigational / Research Priority

Joint disease applications are investigational. The largest series (n=162) reports 91.4% pain resolution in multimodal therapy.

GRADE Evidence Level: Very Low

Case reports, case series, or expert opinion only

162

Arthrosis patients (Sulim 1998)

91.4%

Pain resolution (148/162)

80%

Improved in AS (12/15)

TMJ patients (Sulim 2003)

Osteoarthritis: Sulim (1998) — 2-3 leeches at algic points for 2-3 min combined with manual therapy and phytotherapy. Pain resolved in 91.4% of 162 patients across shoulder, wrist, knee, and hip joints. TMJ arthrosis: Sulim (2003) — 41 patients, 5-6 sessions q2d, 15-20 min. Pain and movement restriction reduced.

Ankylosing spondylitis: Makulova (2003) — paravertebral application in 15 patients; 80% improved pain and spinal mobility. Dupuytren contracture: Serkov (1998) — 10 sessions to flexor tendon fibrosis; scar softening and increased interphalangeal ROM. Additional reports: Starodubskaya (1998) for inflammatory arthritis; Melnik and Razumova (1999) combining apitherapy with hirudotherapy; Zaltsman (1998) documenting reduced disability days.

Published reports — joint disease
Study	Design	Population (n=)	Intervention	Key Outcome	Result
Sulim 1998	Case series (multimodal)	Osteoarthritis (shoulder, wrist, knee, hip) (n=162)	2-3 leeches at algic points, 2-3 min; + manual therapy	Pain resolution	Pain resolved in 148/162 patients (91.4%) Largest series in domain; multimodal limits attribution
Sulim 2003	Case series (multimodal)	TMJ arthrosis (n=41)	2-3 leeches at pain points; 5-6 sessions q2d; 15-20 min	Pain, joint mobility	Reduction or resolution of pain and restricted movement Addresses periarticular microcirculatory impairment
Makulova 2003	Case series	Ankylosing spondylitis (n=15)	Leeches along paravertebral points	Pain, spinal segment mobility	12/15 (80%) reduced pain and increased spinal mobility Pre-biologic era; limited alternative treatments
Serkov 1998	Case series	Dupuytren contracture (n=NR)	3-4 leeches to flexor tendon fibrosis; 10 sessions	Scar softening, interphalangeal ROM	Fibrous scar softening; increased ROM Consistent with collagenase + destabilase fibrinolysis

Эпонимические синдромы (уровень 3)

Investigational / Research Priority

Rare syndrome applications are based on isolated case series and reports (Level IV-V). Insufficient for clinical recommendations outside research.

Reiter Syndrome

Zhavoronkova (1998) and Bondarevsky (1999): classic triad (joint, ocular, urethral) treated with HT. Joint pain, eye pain, and dysuria relieved; sustained clinical effect.

Duplay Syndrome

Zhavoronkova (1998): HT + reflex therapy for scapulohumeral periarthritis. Favorable effect with improved hemodynamic parameters. Combined intervention.

Dupuytren Contracture

Serkov (1998): 3-4 leeches, 10 sessions to flexor tendon fibrosis. Scar softening and increased ROM — consistent with collagenase/destabilase mechanism.

Rossolimo-Melkersson-Rosenthal

Chaban et al. (1999): rare triad (macrocheilitis, facial nerve paresis, scrotal tongue). Restored circulation, reduced edema, multi-system improvement. Single case.

Клинический протокол

Application parameters by disease category
Parameter	Inflammatory Skin	Scleroderma	Joint Disease
Site	On/around lesion	Lesion + meridian acupoints	Algic (pain) points
Leeches	2-6	4-6	2-3
Method	Abuladze (timed)	Abuladze (10-20 min)	Abuladze (2-20 min)
Sessions	1-10	Multiple (unstandardized)	5-10
Frequency	Daily to q2d	Not standardized	Every other day

Direct Lesional

Leeches placed on the lesion or its margins. For psoriatic plaques, placement at the active border maximizes SGS delivery to the inflammatory zone.

Perilesional

For ulcerated or infected lesions, leeches placed on intact skin 1-2 cm from the edge. SGS reaches tissue via diffusion and microcirculation.

Abuladze Method

Timed feeding (2-20 min) rather than full engorgement. Controls blood loss while delivering SGS at pharmacologic concentrations.

Meridian-Based

Rybakova (1998): acupuncture channel selection alongside lesional application. Theory: skin disease as cutaneous manifestation of systemic dysfunction.

Вопросы безопасности

Dermatology-Specific Risks

Application to diseased skin carries risks distinct from healthy tissue. Immunosuppressed patients (SLE, scleroderma on corticosteroids/methotrexate) require prophylactic antibiotics and enhanced wound surveillance.

Risk	Mechanism	Mitigation
Lesional infection	Inflamed skin increases Aeromonas inoculation risk	Prophylactic antibiotics; pre-immersion for immunosuppressed
Prolonged bleeding	Vascularized inflamed skin bleeds longer post-detachment	Hemostatic dressings; coagulation panel; avoid anticoagulants
Koebner phenomenon	Bite trauma may induce new psoriatic plaques	Assess susceptibility; perilesional application; avoid active flares
Hemarthrosis	Theoretical periarticular bleeding into joint space	Avoid deep placement; exclude coagulopathy patients
Cosmetic scarring	Permanent ~2-3 mm triradiate scar on visible areas	Informed consent; assess keloid tendency

Drug Interactions

Medication	Interaction	Action
Systemic corticosteroids	Eglin c potentiates effect; impaired healing	Prophylactic antibiotics; extended monitoring
Methotrexate / Azathioprine	Immunosuppression + Aeromonas risk	Mandatory antibiotics; avoid at nadir
Biologics (TNF/IL-17 inhibitors)	Theoretical infection risk; no published data	Caution; timing relative to injection schedule
Topical corticosteroids	Skin atrophy; impaired local immunity	Discontinue at site 48-72h before treatment
Anticoagulants	Additive effect with hirudin in SGS	Standard precautions; hemostatic dressings

Ключевые выводы

Strong mechanistic rationale: Eglins, bdellins, LDTI, hyaluronidase, collagenase, destabilase, and mast cell antagonists target the processes driving psoriasis, eczema, scleroderma, and arthritis.

Level IV-V evidence: No RCT for any dermatologic indication except wound healing. Small samples, unstandardized outcomes. Wound healing (Tier 2) has the strongest data.

Notable results: 91.4% pain resolution in arthrosis (n=162); zero erysipelas recurrence at 2 years (n=23) vs 30-40% historical rate. Both warrant prospective validation.

Koebner risk: Unresolved safety concern for psoriasis — new plaque induction at bite sites. Prospective evaluation needed before broad recommendation.

Пробелы в доказательной базе и приоритеты исследований

The gap between mechanistic plausibility and clinical evidence is wider in dermatology than nearly any other hirudotherapy domain. ASH supports:

Wound healing RCT: Chronic venous ulcers with standardized endpoints
Psoriasis pilot: Prospective Koebner risk assessment with PASI scoring
Erysipelas trial: HT + antibiotics vs antibiotics alone (2-3 year recurrence)
Scleroderma: Ultrasound-based dermal thickness measurement pre/post HT
Mast cell biomarkers: Tryptase and histamine metabolites in eczema/urticaria
Autoimmune monitoring: Autoantibody and cytokine profiles in scleroderma/SLE

Evidence Quality Summary

Wound healing (Tier 2): Prospective cohort and pilot RCT data. Not FDA-cleared.

All other applications (Tier 3): Level IV-V evidence. No RCT. Strong mechanistic rationale; clinical validation lacking.

Regulatory Disclaimer

No dermatologic or rheumatologic indication has regulatory clearance for medicinal leech therapy. FDA clearance of Hirudo verbana (510(k) K040187) applies only to venous congestion in compromised tissue flaps. All applications on this page are off-label and require institutional oversight and informed consent.

Дерматология и заболевания соединительной ткани

Mixed Evidence Tiers

Investigational Application

International Clinical Evidence

Биологическое обоснование

Anti-Inflammatory Protease Inhibition

Mast Cell Antagonism

Microcirculation Enhancement

Immune Modulation

Tissue Remodeling

Antimicrobial Activity

Convergent Pharmacology

Заживление ран (уровень 2 — клинические доказательства)

Diabetic Foot Ulcers

Chronic Venous Ulcers

Воспалительные заболевания кожи (уровень 3 — исследовательские)

Psoriasis

Koebner Phenomenon

Chronic Eczema & Varicose Eczema

Erysipelas

Erysipelas Recurrence

Other Inflammatory Conditions

Склеродермия и заболевания соединительной ткани (уровень 3)

Артрология: заболевания суставов (уровень 3)

Эпонимические синдромы (уровень 3)

Reiter Syndrome

Duplay Syndrome

Dupuytren Contracture

Rossolimo-Melkersson-Rosenthal

Клинический протокол

Direct Lesional

Perilesional

Abuladze Method

Meridian-Based

Вопросы безопасности

Dermatology-Specific Risks

Drug Interactions

Ключевые выводы

Пробелы в доказательной базе и приоритеты исследований

Evidence Quality Summary

Regulatory Disclaimer

Связанные ресурсы

Clinical Specialties

Dermatological Applications

Wound Healing

Proteinase Inhibitors

Safety Protocols

All Indications